A Wonder Drug Out of Reach

Keytruda, the world's best-selling cancer drug developed by U.S. pharmaceutical giant Merck, has been hailed as a lifeline for hundreds of thousands of cancer patients globally. The immunotherapy drug has demonstrated remarkable efficacy across multiple cancer types, including lung and skin cancer. Yet according to an investigation by the International Consortium of Investigative Journalists (ICIJ) titled 'Cancer Calculus,' this miracle drug remains inaccessible to a vast number of patients worldwide — blocked not by science, but by price.

Why It Matters

The Keytruda story is not simply about one expensive drug. It exposes a core contradiction in the modern pharmaceutical industry: drugs developed with public research funding and government subsidies end up under private patent monopolies, leaving the very patients who need them unable to access treatment. The ICIJ investigation, conducted in collaboration with journalists across multiple countries, details the specific strategies Merck has used to sustain Keytruda's astronomical pricing — strategies with consequences ranging from family financial ruin to the rise of counterfeit drug markets.

The Patent Wall: Keeping Competitors Out

At the heart of Merck's pricing power is its patent strategy. According to the ICIJ investigation, Merck has filed dozens of patents related to Keytruda to delay biosimilar competition by years. Known as 'evergreening,' this approach involves repeatedly filing patents not on the core drug molecule itself, but on formulations, delivery methods, and combinations of indications — effectively extending the monopoly period artificially.

ICIJ's interactive analysis visualizes how densely constructed Keytruda's patent portfolio is. As long as competitor drugs cannot enter the market, pricing remains entirely at Merck's discretion.

Insurance Denials and Courtroom Battles

Price is not the only barrier. Even patients with insurance coverage are being denied Keytruda treatment. According to ICIJ, insurers have refused or delayed physician-prescribed Keytruda doses citing cost reduction or administrative grounds. Patient testimonies describe being denied 'the medication that is keeping you alive.'

Some patients and families have filed lawsuits against insurers. Fighting in court while fighting cancer represents a profound failure of the healthcare system.

Counterfeit Drugs: Desperation's Shadow

Another tragedy born from high drug prices is the spread of counterfeit Keytruda. Cases have emerged of patients who cannot access the genuine drug turning to illegal distribution channels, only to receive counterfeits. Beyond being ineffective, fake cancer treatments can actively worsen a patient's condition — evidence that pricing barriers translate directly into life-threatening consequences.

Historical Context: The Immunotherapy Revolution and the Price Paradox

Keytruda first received FDA approval in 2014, pioneering a new cancer treatment paradigm known as immune checkpoint inhibition. It has since rapidly expanded its approved indications, becoming Merck's core revenue driver. Annual sales reportedly surpassed $25 billion in 2023, making it the world's top-selling drug.

Yet experts have long noted that foundational research at public institutions like the U.S. National Institutes of Health (NIH) played a critical role in Keytruda's development. The structural criticism — that taxpayer-funded research flows into private monopoly profits — has persisted for years without meaningful institutional reform.

The U.S. Inflation Reduction Act (IRA) of 2022 expanded government authority to negotiate drug prices, offering some improvement. However, analysts assess the practical impact on high-cost drugs like Keytruda as limited.

Outlook [Expert Analysis]

The ICIJ investigation is likely to reignite global debates on pharmaceutical access. The WHO and various governments have discussed international standards for essential medicine pricing, but pharmaceutical industry lobbying and intellectual property protections have repeatedly stalled progress.

Experts suggest that once Keytruda biosimilars enter the market — potentially within the next several years — some price competition may emerge. However, the timeline and impact will depend heavily on how effectively Merck's patent portfolio can continue to delay market entry.

For countries including South Korea, the persistent gap in information and negotiating power between national health insurance systems and multinational pharmaceutical companies remains a chronic vulnerability. Analysts suggest this ICIJ investigation could strengthen calls in legislatures and regulatory agencies worldwide for greater drug pricing transparency.

Ultimately, the issue touches on a fundamental philosophical debate: should medicines be treated as public goods or market commodities? With the lives of hundreds of thousands of cancer patients at stake, the answer will depend on how each society chooses to redefine the relationship between healthcare and capital.